01011 NT PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 0.02X | Oper Margin | 6.6% |
|---|---|---|---|
| LT Debt/Equity | N/A | Net Margin | N/A |
| Total Debt/Equity | N/A | Return on Equity | N/A |
| Price/Book | N/A | Return on Assets | N/A |
| (HKD 0.720) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | -28.99 | -56.75 | -158.26 | -74.45 | -182.90 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +48.9 | +64.2 | -112.6 | +59.3 | +56.9 |
| Earnings Per Share (HKD) | -0.047 | -0.215 | -0.664 | -0.392 | -0.968 |
| Earnings Per Share Growth (%) | +78.1 | +67.6 | -69.3 | +59.5 | +57.0 |
| Dividend Per Share (HKD) | No dividend | No dividend | No dividend | No dividend | No dividend |
| P/E* (X) | N/A | N/A | N/A | N/A | N/A |
| Yield (%) | N/A | N/A | N/A | N/A | N/A |
| Dividend Share (%) | N/A | N/A | N/A | N/A | N/A |
| Book NAV (HKD) | -0.452 | -1.607 | -1.417 | -1.423 | -1.357 |
| Auditors' Opinion | N/A | Qualified | Qualified | Qualified | Qualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-03 21:40:22
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 24.158 | 37.96 | -36.4 | 96.003 |
| Operating Result | -26.255 | -63.724 | -58.8 | -89.182 |
| Associates | 0 | 10.244 | -100.0 | 37.039 |
| Profit Before Taxation | -26.255 | -53.48 | -50.9 | -126.609 |
| Taxation | 0 | -0.123 | -100.0 | 16.981 |
| Profit /( Loss) After Taxation | -26.255 | -53.357 | -50.8 | -143.59 |
| Minority Interests | -0.214 | 0 | N/A | 0 |
| Net Profit | -26.041 | -53.357 | -51.2 | -143.59 |
| Earnings Per Share () | -0.0470 | -0.2149 | -78.1 | -0.6635 |
| Announcement Date | 2026-03-31 | 2025-03-31 | NA | 2024-03-28 |
* Annualised
Last Update Time: 2026-04-03 21:40:27
